Cargando…

Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis

BACKGROUND: The resistance to endocrine therapy poses a significant challenge to the management of advanced breast cancer with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (Her-2) negative. The purpose of this study was to further examine the efficacy and safety of cyc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Zhi-Hong, Zhang, Heng, Wei, Deng-Hui, Xie, Li-Li, Xu, Chun-Sen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798229/ https://www.ncbi.nlm.nih.gov/pubmed/35117411 http://dx.doi.org/10.21037/tcr.2019.11.46

Ejemplares similares

Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis
por: Zheng, Jiani, et al.
Publicado: (2020)

Chemical inhibitors of cyclin-dependent kinase (CDKi) improve pancreatic endocrine differentiation of iPS cells
por: Ning, Heming, et al.
Publicado: (2023)

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy
por: Li, Bin-Bin, et al.
Publicado: (2019)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Yoga: An endocrine therapy
por: Kaduskar, Prashant, et al.
Publicado: (2015)

Discussion on Endocrine Therapy
Publicado: (1926)

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy
por: Higham, C E, et al.
Publicado: (2018)

Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
por: Alsfouk, Aisha
Publicado: (2021)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Pre-operative Endocrine Therapy
por: Arthur, Laura M., et al.
Publicado: (2017)

Endocrine Toxicities of Antineoplastic Therapy
por: Puliani, Giulia, et al.
Publicado: (2021)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

The side effects of immune checkpoint inhibitor therapy on the endocrine system
por: Goyal, Itivrita, et al.
Publicado: (2021)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.
por: Roberts, M. M., et al.
Publicado: (1978)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group
por: Fountzilas, Elena, et al.
Publicado: (2020)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
por: Xu, Jing, et al.
Publicado: (2023)

Current and future choices in endocrine therapy
por: Ellis, Matthew
Publicado: (2007)

Integration of endocrine therapy with targeted agents
por: Johnston, Stephen RD
Publicado: (2008)

Pharmacogenomics of endocrine therapy in breast cancer
por: Ingle, James N
Publicado: (2013)

Editorial: Resistance to Endocrine Therapies in Cancer
por: Ranganathan, Prathibha, et al.
Publicado: (2020)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

The immunomodulatory effects of endocrine therapy in breast cancer
por: Huang, Huanhuan, et al.
Publicado: (2021)

Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors
por: Komarla, Anvita, et al.
Publicado: (2023)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy
por: Mohammad, Taj, et al.
Publicado: (2019)

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
por: Augereau, Paule, et al.
Publicado: (2017)

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
por: Al-Toubah, Taymeyah, et al.
Publicado: (2023)

Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis
por: Wang, Jiani, et al.
Publicado: (2022)

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
por: Huifang, Li, et al.
Publicado: (2022)

MMP7 expression regulated by endocrine therapy in ERβ-positive colon cancer cells
por: Fang, Yu-Jing, et al.
Publicado: (2009)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Endocrine therapy: defining the path of least resistance
por: Stone, Andrew, et al.
Publicado: (2014)

Pathways to Endocrine Therapy Resistance in Breast Cancer
por: Haque, Md. Moquitul, et al.
Publicado: (2019)

Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic
por: Barnabei, Agnese, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g2nqg2qec08dper70qlthl3q89